Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1-3. Cancelled
- 4. (Currently amended) The pharmaceutical composition of claim [[1]] 5 wherein the organic phenolic compound is selected from isopropyl-o-cresol, isopropyl-cresol and combinations thereof.
- 5. (Currently amended) The A pharmaceutical composition for treating an infection in an animal of claim 1 comprising:
- (a) at least one antimicrobial compound comprising an organic phenolic compound reacted with wherein one of the at least one Group I salt is a Group I hydroxide base; and
 - (b) a pharmaceutically acceptable carrier for parenteral administration.
- 6. (Currently amended) The pharmaceutical composition of claim 5 wherein the Group I <u>hydroxide</u> base is selected from sodium hydroxide, potassium hydroxide and combinations thereof.
 - 7. (Currently amended) The A pharmaceutical composition of claim 1 comprising:
- (a) at least one antimicrobial compound comprising wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl-cresol chemically reacted with sodium hydroxide and potassium hydroxide; and
 - (b) a pharmaceutically acceptable carrier for parenteral administration.
- 8. (Currently Amended) The pharmaceutical composition of claim [[1]] 5 comprising from 0.1wt% by weight of the pharmaceutical composition to 15wt% by weight of the pharmaceutical composition of antimicrobial compound.

- 9. (Currently Amended) The pharmaceutical composition of claim [[1]] 8 comprising from 0.1wt% of the pharmaceutical composition to 15wt% of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.
- 10. (Currently Amended) The pharmaceutical composition of claim [[1]] 5 comprising from 3.5wt% by weight of the pharmaceutical composition to 10wt% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.
- 11 (Original) The pharmaceutical composition of claim 10 wherein the pharmaceutically acceptable carrier comprises olive oil.
- 12. (Currently amended) The pharmaceutical composition of claim [[1]]5 comprising from 0.1 wt% by weight of the pharmaceutical composition to 1.0 wt% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.
- 13. (Currently amended) The pharmaceutical composition of claim 12 comprising from 0.5 wt% by weight of the pharmaceutical composition to 0.8 wt% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises 0.5 wt% by weight of the pharmaceutically acceptable carrier to 1.0 wt% by weight of the pharmaceutically acceptable carrier of sodium chloride.
 - 14. (Currently Amended) The A pharmaceutical composition comprising: of claim 4
- (a) at least one antimicrobial compound, comprising wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl cresol and wherein there is more isopropyl-o-cresol than isopropyl cresol reacted with at least one Group I salt; and
 - (b) a pharmaceutically acceptable carrier for parenteral administration.
 - 15. (Currently Amended) The A pharmaceutical composition comprising: of claim 1

- (a) wherein the antimicrobial compound comprises between 55wt% of the antimicrobial compound and 99wt% by weight of an the antimicrobial compound comprising of isopropyl-o-cresol or base reacted isopropyl-o-cresol, and
- (b) between 1wt% of the antimicrobial compound and 45wt% by weight of an the antimicrobial compound comprising of isopropyl cresol or base reacted isopropyl cresol.
- 16. (Currently Amended) The pharmaceutical composition of claim [[1]] 15 wherein the composition antimicrobial compound comprises
- (a) between 75wt% of the antimicrobial compound and 99wt% of the antimicrobial compound by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1wt% of the antimicrobial compound and 25wt% of the antimicrobial compound by weight of isopropyl cresol or base reacted isopropyl cresol.
- 17. (Currently Amended) The pharmaceutical composition of claim [[1]] 15 wherein the composition antimicrobial compound comprises
- (a) between 90wt% of the antimicrobial compound and 99wt% of the antimicrobial compound by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1wt% of the antimicrobial compound and 10wt% of the antimicrobial compound by weight of isopropyl cresol or base reacted isopropyl cresol.
- 18. (Currently Amended) The pharmaceutical composition of claim [[1]] 15 wherein the composition antimierobial compound comprises
- (a) between 95wt% of the antimicrobial compound and 99wt% of the antimicrobial compound by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1wt% of the antimicrobial compound and 5wt% of the antimicrobial compound by weight of isopropyl cresol or base reacted isopropyl cresol.
- 19. (Currently amended) The pharmaceutical composition of claim [[1]] 5 wherein the animal is selected from humans, horses, cows, pigs, sheep, goats, rabbits, dogs, cats, chickens, turkeys, ducks and birds.

20. (Currently amended) The pharmaceutical composition of claim [[1]] 5 wherein the infection comprises infection by E. coli, Salmonella spp., Pasteurella spp., Staphyloccocus spp., Streptoccocus spp., Corinebacterium spp., Bacillus spp., Clostridium spp., Spherophorus spp., Candida spp., Trychophyton spp., Microsporum spp., Micobacterium spp., Cryptosporidia spp., Microsporidia spp., Listeria monocytogenes, Lawsonia intracellularis, Treponema desynteriae, Enteroccocus spp., Heamophylus spp., Campylobacter spp., Chlamydia, Brucella spp., or Vibrio spp.

21-36. Cancelled

- 37. (New) The pharmaceutical composition of claim 7, comprising from 0.1% by weight of the pharmaceutical composition to 15% by weight of the pharmaceutical composition of antimicrobial compound.
- 38. (New) The pharmaceutical composition of claim 37, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.
- 39. (New) The pharmaceutical composition of claim 7, comprising from 3.5% by weight of the pharmaceutical composition to 10% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.
- 40. (New) The pharmaceutical composition of claim 39, wherein the pharmaceutically acceptable carrier comprises olive oil.
- 41. (New) The pharmaceutical composition of claim 7 comprising from 0.1 % by weight of the pharmaceutical composition to 1.0 % by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

42. (New) The pharmaceutical composition of claim 7 comprising from 0.5 % by weight of the pharmaceutical composition to 0.8 % by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises 0.5 % by weight of the pharmaceutically acceptable carrier to 1.0 % by weight of the pharmaceutically acceptable carrier earxier of sodium chloride.